Table 2. Heart Rate, blood pressure and ECG findings extracted from aADHD CNS stimulant trials.

		Heart Rate (bpm)	Systoli c BP (mmH g)	Diastol ic BP (mmHg )	QTc Interval (msec)	QRS Interval (msec)	PR Interval (msec)
Study	Drug Group	Mean±S E	Mean±S E	Mean±S E	Mean±S E	Mean±S E	Mean±S E
Weisler (2006)	Placebo	1.9±1.3	−1.9±1.3	NR	−2.8±2.5	NR	NR
	MAS-XR	5.2±07	1.7±1.2	NR	4.5±1.8	NR	NR
Spencer (2007)	PBO	−1.4±1.3	−1.7±1.6	0.3±1.1	NR	NR	NR
	d-MPH-ER	4.4±0.8	0.5±0.9	1.0±0.6	NR	NR	NR
Biederman (2007)	Placebo	−4.7±1.1	−1.2±1.1	−1.5±0.8	0.5±1.7	0.5±0.8	−1.1±1.3
	OROS-MPH	4.5±1.3	3.5±1.4	4.0±1.0	1.9±1.9	−1.2±0.7	−1.2±1.4
	MPH-tid	5.9±1.3	2.0±1.2	2.1±0.9	6.1±1.6	−1.2±1.0	−2.5±1.2
Medori (2008)	Placebo	2.7±1.7	1.1±2.4	−1.8±1.7	-	-	-
	OROS-MPH	5.5±1.1	1.0±1.2	−0.2±0.9	-	-	-
Adler (2008)	Placebo	0.0±1.1	−0.5±1.0	1.1±0.1	−0.3±1.9	0.0±0.7	NR
					1.6±1.8	-	NR
		4.1±0.5	0.8±0.4	1.2±0.3		0.03±0.
	LDX					3
Adler (2009)	Placebo	−1.6±0.8	−0.5±0.9	0.4±0.7	NR	NR	NR
	OROS-MPH	6.3±0.9	−1.2±0.8	1.1±0.6	NR	NR	NR
Rosler (2009)	Placebo	1.0±1.8	2.0±2.4	0.0±1.5	-	-	-
	MPH-ER	4.0±1.6	3.0±1.2	0.0±0.8	-	-	-
Casas (2011)	Placebo	1.0±1.1	−2.0±1.2	0.4±0.9	NR	NR	NR
	OROS-MPH	4.3±0.9	1.6±0.9	1.1±0.7	NR	NR	NR
Retz (2012)	Placebo	1.0±1.9	2.0±1.2	−2.0±1.6	-	-	-
	OROS-MPH	2.0±2.0	1.0±1.4	3.0±1.7	-	-	-
Biederman (2012)	Placebo	-0.6±2.2	−1.7±2.5	−2.3±2.2	0.6±2.7	−0.2±0.8	0.1±2.2
	LDX	15.9±2 9	4.2±2.9	2.9±1.9	9.7±2.0	0.8±0.9	−4.9±2.0
Pooled Estimate	Placebo	−0.5±0.7	−0.9±0.4	0.2±0.4	-	-	-
	CNS Stimulant	5.0±0.5a	1.2±0.4b	1.2±0.3c	-	-	-

MAS-XR (mixed amphetamine salts, extended release), d-MPH-ER (dexmethylphenidate extended-release), OROS-MPH (osmotic release oral system methylphenidate), IR-MPH (immediate release methylphenidate), LDX (lisdexamphetamine), MPH-ER (extended release methylphenidate). Statistically significant change scores within treatment group

^a(p<0.001)

^b(p=0.004)

^c(p<0.001).